



NDA 22-015/S-003

Schering-Plough HealthCare Products
Attention: Anna Kalika
Manager, Regulatory Affairs
556 Morris Avenue
Summit, NJ 07901-1330

Dear Ms. Kalika:

Please refer to your supplemental new drug application dated June 6, 2008, received June 9, 2008, submitted under section 505(b) of the Federal Food, Drug, and Cosmetic Act for MiraLAX® (17 g polyethylene glycol 3350) powder for solution.

This “Changes Being Effected” supplemental new drug application proposes a new child resistant unit dose foil sachet and a revision to the label to accommodate the new child resistant design.

We have completed our review of this application. This application is approved, effective on the date of this letter, for use as recommended in the agreed upon labeling text.

The final printed labeling (FPL) must be identical to the enclosed labeling (one dose, child resistant foil sachet with Drug Facts) and must be formatted in accordance with the requirements of 21 CFR 201.66, where applicable.

Please submit an electronic version of the FPL according to the guidance for industry titled *Providing Regulatory Submissions in Electronic Format - NDA*. Alternatively, you may submit 20 paper copies of the FPL as soon as it is available but no more than 30 days after it is printed. Individually mount 15 of the copies on heavy-weight paper or similar material. For administrative purposes, designate this submission "**FPL for approved supplement NDA 22-015/S-003.**" Approval of this submission by FDA is not required before the labeling is used.

If you issue a letter communicating important information about this drug product (i.e., a “Dear Health Care Professional” letter), we request that you submit a copy of the letter to this NDA and a copy to the following address:

MEDWATCH
Food and Drug Administration
5515 Security Lane
HFD-001, Suite 5100
Rockville, MD 20857

Please submit one market package of the drug product when it is available.

We remind you that you must comply with reporting requirements for an approved NDA (21 CFR 314.80 and 314.81).

If you have any questions, call Mary Vienna, Regulatory Project Manager, at (301) 796-4150.

Sincerely,

{See appended electronic signature page}

Andrea Leonard Segal, M.D.
Director
Division of Nonprescription Clinical Evaluation
Office of Nonprescription Products
Center for Drug Evaluation and Research

Enclosure

**This is a representation of an electronic record that was signed electronically and
this page is the manifestation of the electronic signature.**

/s/

Andrea Segal
12/2/2008 11:45:52 AM